Immune response to sipuleucel-T in prostate cancer

about

Anti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell-Based Vaccine in Prostate Cancer-Bearing Mice.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.Prostate cancer health disparities: An immuno-biological perspective.

P2860

Q34993204-E1CA8311-6C67-4444-B2D3-BC602B259D41 Q37518336-5E85760D-1D7C-40E4-BAFE-6D3AF9106B5C Q46537204-DAFC879B-3C62-4010-BFBC-4D8CF13E15C8

P2860

Immune response to sipuleucel-T in prostate cancer

Item

http://www.wikidata.org/entity/Q38161390

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Immune response to sipuleucel-T in prostate cancer

@en

type

Item

label

Immune response to sipuleucel-T in prostate cancer

@en

prefLabel

Immune response to sipuleucel-T in prostate cancer

@en

P1476

Immune response to sipuleucel-T in prostate cancer

@en

P2093

Eddie Thara

http://www.w3.org/2001/XMLSchema#string

Jacek K Pinski

http://www.w3.org/2001/XMLSchema#string

Mary E Reed

http://www.w3.org/2001/XMLSchema#string

Michael Luther

http://www.w3.org/2001/XMLSchema#string

Monica Averia-Suboc

http://www.w3.org/2001/XMLSchema#string

Tanya B Dorff

http://www.w3.org/2001/XMLSchema#string

P2860

Improved endpoints for cancer immunotherapy trials

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer

Cancer statistics, 2010

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors

P304

420-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/CANCERS4020420

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

David I Quinn

P577

2012-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258429707

http://www.w3.org/2001/XMLSchema#string

P698

24213318

http://www.w3.org/2001/XMLSchema#string

P932

3712699

http://www.w3.org/2001/XMLSchema#string

Immune response to sipuleucel-T in prostate cancer

about

P2860

P2860

Immune response to sipuleucel-T in prostate cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932